About
Verge Genomics has developed CONVERGE®, an AI-powered drug discovery platform utilizing a large, proprietary human multi-omics database to identify and validate drug candidates for neurodegenerative diseases. Their platform leverages machine learning to analyze human tissue data, enabling the rapid identification of novel targets and accelerating drug development – most notably, their lead compound VRG50635, a PIKfyve inhibitor for ALS, entered clinical trials just four years after initial research. Currently focused on ALS, Parkinson’s Disease, and Frontotemporal Dementia, Verge aims to deliver breakthrough treatments for diseases with limited or no effective therapies.
Focus Areas
Technology Focus
Key People
Quick Stats
Explore More
Similar Companies
Tempus AI
Chicago, United States
Xaira Therapeutics
San Francisco, United States
BPGbio
Framingham, United States
Terray Therapeutics
Pasadena, United States